UCSD, U of Manitoba, St. Boniface Hospital Albrechtsen Research Center, WinSanTor deal

Have you been diagnosed with peripheral neuropathy? We can help.

The organizations granted WinSanTor an exclusive license to develop and commercialize small molecule antagonists of muscarinic receptor to treat peripheral neuropathy. The lead compound, WST-057, is in Phase I trials for the indication, with Phase II trials slated for 2017. WinSanTor declined to disclose financial details, and St. Boniface did not respond in time for publication. The universities did not respond to inquiries.

St. Boniface Hospital Albrechtsen Research Center, Winnipeg, Manitoba
University of California San Diego, La Jolla, Calif.
University of Manitoba, Winnipeg, Manitoba
WinSanTor Inc., San Diego, Calif.
Business: Neurology

 

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Sign up for our newsletter

Free to join.

Your privacy is very important to us. We will never share your information without your written consent.

WinSanTor is based in San Diego, California, USA

Share This Story, Choose Your Platform!

Related Posts

Senior Asian man sitting in bed cannot sleep from insomnia
Neuropathy

Why Is My Peripheral Neuropathy Worse at Night?

Why does neuropathic pain flare up at night? Although sleep issues may not seem like the most significant issue when managing peripheral neuropathy, it is essential to tackle both neuropathy

Senior man contemplating at home
Neuropathy

Peripheral Neuropathy and Amyloidosis

The connection between peripheral neuropathy and amyloidosis is often overlooked and yet to be fully understood. With March being Amyloidosis Awareness Month, much is to be said and learned about

Have you been diagnosed with peripheral neuropathy? We can help.